Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Other Non-Current Assets (2018 - 2025)

Historic Other Non-Current Assets for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $1.5 million.

  • BioNexus Gene Lab's Other Non-Current Assets fell 2591.86% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 2591.86%. This contributed to the annual value of $1.5 million for FY2024, which is 5490.79% down from last year.
  • Latest data reveals that BioNexus Gene Lab reported Other Non-Current Assets of $1.5 million as of Q3 2025, which was down 2591.86% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Other Non-Current Assets peaked at $3.3 million during Q1 2024, and registered a low of $849744.0 during Q2 2022.
  • In the last 5 years, BioNexus Gene Lab's Other Non-Current Assets had a median value of $1.5 million in 2025 and averaged $1.8 million.
  • In the last 5 years, BioNexus Gene Lab's Other Non-Current Assets soared by 24517.38% in 2021 and then crashed by 5490.79% in 2024.
  • BioNexus Gene Lab's Other Non-Current Assets (Quarter) stood at $1.5 million in 2021, then fell by 2.48% to $1.5 million in 2022, then surged by 119.33% to $3.3 million in 2023, then crashed by 54.91% to $1.5 million in 2024, then grew by 3.16% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.5 million for Q2 2025, and $2.5 million during Q1 2025.